newsfilter
← Latest News
GlobeNewswire·

Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

CTKB
  • A Delaware jury ruled in favor of Cytek Biosciences on three of four patent claims asserted by Beckman Coulter, finding noninfringement and invalidity.
  • The jury found no literal infringement but determined infringement under the doctrine of equivalents for one claim.
  • The jury awarded Beckman Coulter $20 million in lost profits and $36 million in royalties, totaling $56 million in past damages.
  • Cytek intends to file post-verdict motions challenging the doctrine of equivalents finding and the associated damages award.
  • CEO Dr. Wenbin Jiang stated the company disagrees with the single adverse finding and plans to pursue all available remedies, including a potential appeal to the Federal Circuit.
  • The verdict will not require changes to Cytek's product offerings or operations, with spectral flow cytometry products remaining available globally.
  • Cytek remains committed to investing in its Full Spectrum Profiling™ platform and delivering cell analysis solutions.
  • Cytek's products are designated for research use only, with limited clinical availability for specific systems in China and the European Union.
  • The press release includes forward-looking statements regarding potential litigation outcomes, financial impacts, and future performance risks.